United States💼 BusinessProgressiveOverlooked by conservatives
STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
An investigation by the International Consortium of Investigative Journalists reveals that four major pharmaceutical companies, including Merck, Eli Lilly, Novartis, and AstraZeneca, paid tens of millions of dollars to Russian intermediaries such as R-Pharm between 2020 and 2023. These payments were made to supply essential medications to Russian government entities within a system characterized by corruption, which allegedly inflated prices and restricted patient access to critical treatments like cancer drugs. Whistleblowers claim the firms awarded excessive bonuses to these middlemen despite their involvement in questionable bidding practices and allegations of bid rigging or anticompetitive behavior. Separately, investors and medical professionals are closely monitoring upcoming clinical trial results for Kymera Therapeutics' experimental eczema treatment, KT-621, which analysts describe as potentially having significant implications for the market dominated by the leading immunology drug Dupixent.
Whistleblower documents reveal that four major pharmaceutical manufacturers transferred tens of millions of dollars to Russian intermediaries between 2020 and 2023. The payments went to proxies supplying essential medications to Russian government bodies within a system characterized by corruption. This structure allegedly maintained elevated pricing while restricting patient access to critical treatments for conditions such as cancer. The disclosures identify Merck, Eli Lilly, Novartis, and AstraZeneca as the companies involved. They provided excessive bonuses to R-Pharm and other middlemen despite ongoing investigations into those firms for bid rigging and anticompetitive behavior. The investigation stems from confidential reports submitted in 2024 and 2025. These filings detail how the drugmakers operated through a network of distributors entangled in allegations of improper payments and conflicts of interest. The central figure in these dealings is Alexey Repik, founder of R-Pharm. A Moscow native and trained economist, Repik established the company in 2001 using personal savings and a loan from his mother. Over time, R-Pharm evolved into a key intermediary for Western pharmaceutical firms bidding on large-scale government medical contracts. Repik built a substantial fortune during this period. His assets included a residence in San Francisco and a collection of modern art and Japanese prints. He gained recognition in high-stakes poker circles at Western luxury casinos, known for an aggressive playing style. Despite questions regarding his proximity to power, Repik denied having direct backing from officials in a 2015 interview. However, he cultivated significant political ties. He met privately with Russian President Vladimir Putin, attended the World Economic Forum, and participated in Donald Trump’s 2017 inaugural celebrations. Repik posted images on social media showing himself wearing a campaign hat on election night in 2016. Later investigative work linked an offshore entity associated with Repik to a private jet reportedly used by one of Putin’s daughters. Merck, based in New Jersey, formed a strategic alliance with R-Pharm in 2009. At that time, the Russian firm was expanding its operations and forming partnerships with other Western entities. The collaboration deepened over the years, involving shared manufacturing expertise and joint production of medicines. R-Pharm also faced scrutiny from Russia’s Federal Antimonopoly Service. Investigators examined whether the firm coordinated bids with other distributors or engaged in practices designed to inflate drug prices and manipulate contract awards. The current reporting is part of a broader initiative examining how pharmaceutical companies sustain market dominance. The project investigates strategies used to preserve multibillion-dollar monopolies and keep cancer medication costs high. Critics argue this approach depletes global healthcare resources and harms patients. The whistleblower accounts suggest that the payment structures persisted even as regulatory bodies raised concerns about the integrity of the bidding processes. Separate developments in the pharmaceutical sector continue to draw investor attention. An experimental therapy aimed at competing with Dupixent, currently the leading immunology drug, is nearing a pivotal milestone. Kymera Therapeutics intends to release data from a mid-stage clinical trial of its lead candidate, KT-621, for eczema treatment before the year ends. Financial analysts describe the upcoming results as highly consequential for the field of immunology and inflammation disorders. The outcome will likely impact Kymera’s valuation and competitive landscape. Millions of individuals in the United States living with eczema await potential therapeutic advances. The timing of these announcements coincides with heightened scrutiny of industry practices globally. Regulatory and legal implications remain unclear for the four named corporations. The whistleblower claims focus on the period from 2020 to 2023. During this window, the alleged excessive bonuses flowed to R-Pharm and its associates. The reports highlight a disconnect between corporate compliance standards and the operational realities of doing business in specific geopolitical contexts. The involvement of sanctioned individuals adds complexity to the narrative. Repik is currently subject to sanctions due to his status as an oligarch close to the Russian leadership. The distribution of life-saving drugs through such channels raises ethical and practical questions. Patients with serious ailments depended on these supplies. Yet the mechanisms used to deliver them allegedly contributed to higher overall costs and limited availability. The interplay between commercial interests and public health outcomes remains a focal point of international discourse. As the trial data for KT-621 approaches, the industry faces dual pressures from scientific innovation and ethical accountability. Stakeholders including investors, physicians, and policymakers are monitoring both fronts closely. The coming weeks will provide clarity on the efficacy of the new eczama treatment. Simultaneously, further details may emerge regarding the historical financial arrangements in Russia.
Go to the primary sources (2)
The official sources this coverage is built on. Read them directly to bypass framing.
An investigation by the International Consortium of Investigative Journalists reveals that four major pharmaceutical companies, including Merck, Eli Lilly, Novartis, and AstraZeneca, paid tens of millions of dollars to Russian intermediaries such as R-Pharm between 2020 and 2023. These payments were made to supply essential medications to Russian government entities within a system characterized by corruption, which allegedly inflated prices and restricted patient access to critical treatments like cancer drugs. Whistleblowers claim the firms awarded excessive bonuses to these middlemen despite their involvement in questionable bidding practices and allegations of bid rigging or anticompetitive behavior. Separately, investors and medical professionals are closely monitoring upcoming clinical trial results for Kymera Therapeutics' experimental eczema treatment, KT-621, which analysts describe as potentially having significant implications for the market dominated by the leading immunology drug Dupixent.
Bias read (Progressive): The article relies exclusively on investigative journalism alleging corporate corruption and uses strong normative language like 'corrupt system' and 'dubious practices' without presenting defensive counterarguments from the accused pharmaceutical companies.
An investigation by the International Consortium of Investigative Journalists reveals that major pharmaceutical companies, including Merck, partnered with R-Pharm, a Russian distributor led by oligarch Alexey Repik, who has ties to President Vladimir Putin. Despite facing antitrust investigations and questions regarding insider connections, R-Pharm secured lucrative government contracts for cancer drugs like Keytruda. Whistleblower reports indicate that four pharma giants paid tens of millions of dollars through proxies within a system characterized by alleged bid rigging, conflicts of interest, and inflated prices. Repik, who amassed significant wealth and international prestige, previously denied having political backing but was later linked to assets used by members of the Russian leadership.
Bias read (Progressive): The article employs critical language such as 'corrupt system' and highlights the oligarch's proximity to authoritarian power, reflecting a progressive stance against state-corporate collusion.
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.